Celgene Corp. (CELG) News Nov 18, 2014, 7:51 p.m.
Post# of 250602
Posted On: 11/18/2014 9:55:52 PM
Celgene Corp. (CELG) News Nov 18, 2014, 7:51 p.m.
MarketWatch News on CELG
5 charts show how stock repurchases boost prices 6:00 a.m. Today - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 10:20 a.m. July 1, 2014 - Michael Ashbaugh
Loading more headlines...
Advertisement
Other News on CELG
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous 8:10 p.m. Today - TheStreet.com
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells 6:02 p.m. Today - TheStreet.com
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Today - Seeking Alpha
3 Stocks Reiterated As A Buy: CELG, BAC, XOM 1:29 p.m. Today - TheStreet.com
Celgene presents Phase 3 Otezla data 10:05 a.m. Today - Seeking Alpha
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy! 12:35 p.m. Nov. 17, 2014 - Seeking Alpha
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold? 5:00 a.m. Nov. 15, 2014 - TheStreet.com
Medical Stocks Tumble But Most Of IBD 50 Trading Well 5:47 p.m. Nov. 14, 2014 - Investors Business Daily
Biotech Stocks Hit: Stock Market To See New Leaders? 5:22 p.m. Nov. 14, 2014 - Investors Business Daily
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog 3:40 p.m. Nov. 14, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog 5:00 p.m. Nov. 13, 2014 - Zacks.com
Celgene Is Up 22% Over The Past Month; What Do Technicians Think? 1:12 p.m. Nov. 13, 2014 - benzinga.com
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
ModernGraham Quarterly Valuation Of Celgene Corporation 5:11 p.m. Nov. 12, 2014 - Seeking Alpha
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Nov. 12, 2014 - 247WallSt.com
Celgene's Management Presents at Credit Suisse Healthcare Conference (Transcript) 5:48 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: INTC, CAT, CELG 4:44 p.m. Nov. 11, 2014 - TheStreet.com
Loading more headlines...
Press Releases on CELG
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Today - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Loading more headlines...
MarketWatch News on CELG
5 charts show how stock repurchases boost prices 6:00 a.m. Today - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 10:20 a.m. July 1, 2014 - Michael Ashbaugh
Loading more headlines...
Advertisement
Other News on CELG
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous 8:10 p.m. Today - TheStreet.com
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells 6:02 p.m. Today - TheStreet.com
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Today - Seeking Alpha
3 Stocks Reiterated As A Buy: CELG, BAC, XOM 1:29 p.m. Today - TheStreet.com
Celgene presents Phase 3 Otezla data 10:05 a.m. Today - Seeking Alpha
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy! 12:35 p.m. Nov. 17, 2014 - Seeking Alpha
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold? 5:00 a.m. Nov. 15, 2014 - TheStreet.com
Medical Stocks Tumble But Most Of IBD 50 Trading Well 5:47 p.m. Nov. 14, 2014 - Investors Business Daily
Biotech Stocks Hit: Stock Market To See New Leaders? 5:22 p.m. Nov. 14, 2014 - Investors Business Daily
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog 3:40 p.m. Nov. 14, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog 5:00 p.m. Nov. 13, 2014 - Zacks.com
Celgene Is Up 22% Over The Past Month; What Do Technicians Think? 1:12 p.m. Nov. 13, 2014 - benzinga.com
3 Stocks Underperforming Today In The Drugs Industry 12:06 p.m. Nov. 13, 2014 - TheStreet.com
ModernGraham Quarterly Valuation Of Celgene Corporation 5:11 p.m. Nov. 12, 2014 - Seeking Alpha
Biotech Short Interest Becomes Stock Specific 8:11 a.m. Nov. 12, 2014 - 247WallSt.com
Celgene's Management Presents at Credit Suisse Healthcare Conference (Transcript) 5:48 p.m. Nov. 11, 2014 - Seeking Alpha
Amgen's brodalumab beats Stelara in Phase 3 trial 4:52 p.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: INTC, CAT, CELG 4:44 p.m. Nov. 11, 2014 - TheStreet.com
Loading more headlines...
Press Releases on CELG
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Today - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Loading more headlines...
(0)
(0)Scroll down for more posts ▼